The damage to AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) from Wainua's trial failure is less about the numbers than about a dent ...

AstraZeneca (LSE:AZN) and Ionis Pharmaceuticals reported that their drug Wainua (eplontersen) did not meet the primary ...

AstraZeneca sees stock market value slump by more than £20bn after drug setback - The FTSE 100 firm found the Wainua drug ...

Astra's shares tumbled 10.5% after it said its Wainua drug - which it is developing with Ionis - failed to reduce deaths ...

Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...

Curious whether AstraZeneca is priced attractively today, or if recent enthusiasm has already been baked into the stock.

AstraZeneca loses £20 billion in value after disappointing trial results for a key heart disease drug. Find out more.

AstraZeneca is in focus after analysts trimmed their fair value estimate for the stock slightly from £165.09 to £164.85, signaling a measured shift in valuation work rather than a sharp rethink. That ...

For dollar values in this table, the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp). In the table above, R&D expense, SG&A ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...